Nucleic Acid Therapeutics Market to Reach US$ 14.42 Billion by 2032 at 10.9% CAGR; North America Leads with 38% Share - Key Players: Alnylam, Ionis, Novartis

The global Nucleic Acid Therapeutics Market reached US$ 5.64 billion in 2024 and is expected to reach US$ 14.42 billion by 2032, growing at a CAGR of 10.9% during the forecast period 2025-2032. Market growth is driven by rapid advancements in genetic medicine, increasing prevalence of genetic and rare disorders, and strong investment in biotechnology and pharmaceutical research.

Nucleic acid therapeutics are advanced treatment modalities that utilize DNA, RNA, or chemically modified nucleic acids to prevent or treat diseases by directly targeting genetic material within cells. These therapies function by correcting faulty genes, regulating gene expression, or inhibiting the production of disease-causing proteins. Key approaches include gene therapy, RNA interference (RNAi), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies. Growing clinical success in oncology, neurological disorders, and rare inherited diseases, along with expanding regulatory approvals and technological innovations in delivery systems, is significantly strengthening the long-term outlook of the nucleic acid therapeutics market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nucleic-acid-therapeutics-market?sai-v
The Nucleic Acid Therapeutics Market refers to the global industry focused on developing and commercializing RNA- and DNA-based therapies for the treatment and prevention of genetic, infectious, and chronic diseases.

Key Developments
✅ January 2026: Regulatory agencies granted priority review status to several next-generation mRNA and siRNA therapeutic candidates targeting rare genetic disorders, signaling accelerated approval timelines.

✅ December 2025: A major biotechnology company unveiled expanded clinical data showing improved efficacy and safety profiles for its lipid nanoparticle delivery platform in mRNA therapeutics.

✅ December 2025: New guidelines emerged from global health authorities recommending standardized frameworks for nucleic acid therapeutic manufacturing quality and potency assessment.

✅ November 2025: Academic and industry collaborations increased for CRISPR-based gene editing therapies, with several preclinical programs advancing into early clinical trials.

✅ October 2025: Advances in delivery technologies, including peptide and polymer conjugates, significantly enhanced targeted tissue uptake and reduced off-target effects in oligonucleotide therapies.

✅ September 2025: Expanded insurance coverage policies for certain gene silencing therapies improved patient access in key markets, supporting broader adoption and reimbursement pathways.

Mergers & Acquisitions
✅ December 2025: A leading pharmaceutical company completed the acquisition of a specialized nucleic acid delivery technology firm to strengthen its mRNA and siRNA therapeutic pipeline.

✅ November 2025: A mid-size biotech focusing on antisense oligonucleotide therapies entered a strategic acquisition by a global biopharma group to accelerate late-stage development programs.

✅ October 2025: A major contract development and manufacturing organization (CDMO) expanded its nucleic acid therapeutics services through acquisition of a GMP facility dedicated to oligonucleotide and vector production.

Key Players
Ionis Pharmaceuticals | Alnylam Pharmaceuticals, Inc. | Gilead Sciences, Inc. | AstraZeneca | Sarepta Therapeutics, Inc. | Creative Biolabs | GSK plc | Novartis AG | BioNTech SE | Silence Therapeutics

Key Highlights
Alnylam Pharmaceuticals, Inc. - Holds 22.4% share, driven by leadership in RNA interference therapeutics, multiple commercialized RNAi drugs, and a strong late-stage clinical pipeline.

Ionis Pharmaceuticals - Holds 18.7% share, supported by pioneering antisense oligonucleotide technology, broad partnered pipeline, and long-standing collaborations with major pharmaceutical companies.

Novartis AG - Holds 13.9% share, leveraging global commercialization capabilities, strong R&D investment in RNA-based therapies, and extensive clinical development expertise.

GSK plc - Holds 11.6% share, driven by expanding RNA therapeutics research, strategic acquisitions, and focus on rare and chronic disease indications.

AstraZeneca - Holds 9.8% share, supported by strong biologics and precision medicine platforms, growing RNA-focused R&D programs, and global clinical infrastructure.

Gilead Sciences, Inc. - Holds 8.1% share, benefiting from deep expertise in antiviral and specialty therapeutics, along with increasing investments in RNA-based drug development.

Sarepta Therapeutics, Inc. - Holds 6.4% share, focused on RNA-based treatments for rare neuromuscular disorders, with strong regulatory experience and orphan drug positioning.

BioNTech SE - Holds 5.2% share, leveraging mRNA technology leadership, oncology-focused RNA pipelines, and advanced manufacturing capabilities.

Silence Therapeutics - Holds 2.5% share, driven by proprietary siRNA platform technologies and partnerships targeting cardiometabolic and rare diseases.

Creative Biolabs - Holds 1.4% share, providing RNA-based research services and preclinical development support for academic and pharmaceutical clients.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=nucleic-acid-therapeutics-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
- Rising prevalence of genetic disorders, cancer, and infectious diseases increasing demand for advanced gene-based therapies.

- Growing clinical success of RNA- and DNA-based therapeutics, including mRNA, antisense oligonucleotides, and siRNA therapies.

- Advancements in nucleic acid delivery technologies improving cellular uptake, stability, and targeted therapeutic action.

- Increasing investment in biotechnology research, genomic medicine, and precision therapeutics by public and private organizations.

- Expanding regulatory approvals and accelerated pathways supporting commercialization of innovative nucleic acid-based treatments.

Industry Developments
- Continuous innovation in mRNA, siRNA, antisense, and gene-silencing platforms to address complex and previously untreatable diseases.

- Rising focus on advanced delivery systems such as lipid nanoparticles, viral vectors, and conjugation technologies.

- Strategic partnerships and licensing agreements between biotechnology firms and pharmaceutical companies to accelerate development pipelines.

- Expansion of manufacturing capabilities for large-scale, GMP-compliant nucleic acid drug production.

- Increased emphasis on rare diseases, oncology, and personalized medicine applications within nucleic acid therapeutic pipelines.

Regional Insights
North America - 38% share: "Driven by strong biotechnology ecosystems, high R&D investments, early adoption of advanced gene therapies, and favorable regulatory frameworks."

Europe - 26% share: "Supported by robust academic research, increasing clinical trial activity, government funding for genomic medicine, and growing biotech collaborations."

Asia Pacific - 28% share: "Fueled by expanding biotechnology infrastructure, rising investment in genomic research, growing clinical development activity, and increasing adoption of precision medicine."

Latin America - 5% share: "Driven by gradual expansion of biotech research capabilities, increasing participation in global clinical trials, and improving regulatory environments."

Middle East & Africa - 3% share: "Supported by emerging life sciences initiatives, healthcare investment growth, and increasing focus on advanced therapeutic research."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nucleic-acid-therapeutics-market?sai-v

Key Segments

By Category
Antisense oligonucleotides (ASOs) hold a significant share of the market, driven by their established clinical use and targeted gene-silencing capabilities. Small interfering RNA (siRNA) represents a major segment, supported by increasing regulatory approvals and expanding therapeutic pipelines. Messenger RNA (mRNA) is witnessing rapid growth, driven by its success in vaccines and growing adoption in therapeutic and protein replacement applications. Self-amplifying RNA (saRNA) is emerging steadily, supported by its ability to achieve higher protein expression at lower doses and ongoing advancements in RNA delivery technologies.

By Application
Cancer applications dominate the market, driven by rising oncology research, precision medicine approaches, and increasing investment in RNA-based therapeutics. Viral infections account for a substantial share, supported by strong demand for vaccines and antiviral therapies. Genetic disorders represent a growing segment, driven by unmet medical needs and advances in gene-targeted treatments. Other applications, including autoimmune and metabolic disorders, contribute steadily to overall market expansion.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.